Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

COPD and cognitive impairment: the role of hypoxemia and oxygen therapy

Authors Neeta Thakur, Paul D Blanc, Laura J Julian, et al

Published Date August 2010 Volume 2010:5 Pages 263—269

DOI http://dx.doi.org/10.2147/COPD.S10684

Published 10 August 2010

Neeta Thakur1, Paul D Blanc2, Laura J Julian1, Edward H Yelin3, Patricia P Katz3, Stephen Sidney4, Carlos Iribarren4, Mark D Eisner1,2

1Department of Medicine, 2Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, 3Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco, CA, USA, 4Division of Research, Kaiser Permanente, Oakland, CA, USA

Background: Several studies have shown an association between chronic obstructive pulmonary disease (COPD) and cognitive impairment. These studies have been limited by methodological issues such as diagnostic uncertainty, cross-sectional design, small sample size, or lack of appropriate referent group. This study aimed to elucidate the association between COPD and the risk of cognitive impairment compared to referent subjects without COPD. In patients with established COPD, we evaluated the impact of disease severity and impairment of respiratory physiology on cognitive impairment and the potential mitigating role of oxygen therapy.

Methods: We used the Function, Living, Outcomes and Work (FLOW) cohort study of adults with COPD (n = 1202) and referent subjects matched by age, sex, and race (n = 302) to study the potential risk factors for cognitive impairment among subjects with COPD. Cognitive impairment was defined as a Mini-Mental State Exam score of <24 points. Disease severity was using Forced Expiratory Volume in one second (FEV1); the validated COPD Severity Score; and the BMI (Body Mass Index), Obstruction, Dyspnea, Exercise Capacity (BODE) Index. Multivariable analysis was used to control for confounding by age, sex, race, educational attainment, and cigarette smoking.

Results: COPD was associated with a substantive risk of cognitive impairment compared to referent subjects (odds ratio [OR] 2.42; 95% confidence interval [CI] 1.043–6.64). Among COPD patients, none of the COPD severity measures were associated with the risk of cognitive impairment (P > 0.20 in all cases). Low baseline oxygen saturation was related to increased risk of cognitive impairment (OR for oxygen saturation ≤ 88% (OR 5.45; 95% CI 1.014–29.2; P = 0.048). Conversely, regular use of supplemental oxygen therapy decreased the risk for cognitive impairment (OR 0.14; 95% CI 0.07–0.27; P < 0.0001).

Conclusion: COPD is a major risk factor for cognitive impairment. Among patients with COPD, hypoxemia is a major contributor and regular use of home oxygen is protective. Health care providers should consider screening their COPD patients for cognitive impairment.

Keywords: chronic obstructive pulmonary disease

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

The impact of SHS exposure on health status and exacerbations among patients with COPD

Mark D Eisner, Carlos Iribarren, Edward H Yelin, Stephen Sidney, et al.

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:169-176

Published Date: 6 May 2009

Readers of this article also read:

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S, Sternberg CN

Drug Design, Development and Therapy 2015, 9:3325-3339

Published Date: 29 June 2015

Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units

Sundh J, Johansson G, Larsson K, Lindén A, Löfdahl CG, Janson C, Sandström T

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:173-183

Published Date: 22 January 2015

Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: in vivo study

Schlachter EK, Widmer HR, Bregy A, Lönnfors-Weitzel T, Vajtai I, Corazza N, Bernau VJP, Weitzel T, Mordasini P, Slotboom J, Herrmann G, Bogni S, Hofmann H, Frenz M, Reinert M

International Journal of Nanomedicine 2011, 6:1793-1800

Published Date: 26 August 2011

Hypoxemia in patients with COPD: cause, effects, and disease progression

Brian D Kent, Patrick D Mitchell, Walter T McNicholas

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:199-208

Published Date: 14 March 2011

Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease

Alicia Lacoma, Cristina Prat, Felipe Andreo, et al

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:157-169

Published Date: 28 February 2011

Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis

Safaa Sebak, Maryam Mirzaei, Meenakshi Malhotra, et al

International Journal of Nanomedicine 2010, 5:525-532

Published Date: 15 September 2010

Management of COPD in general practice in Denmark – participating in an educational program substantially improves adherence to guidelines

Charlotte Suppli Ulrik, Ejvind Frausing Hansen, Michael Skov Jensen, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:73-79

Published Date: 11 March 2010